Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Vitrakvi (larotrectinib) for Advanced Solid Tumours with NTRK Gene Fusion

Vitrakvi® (larotrectinib) is an oral kinase inhibitor indicated to treat advanced solid tumours with neurotrophic receptor tyrosine kinase gene fusion. Photo: PRNewsfoto/Bayer.

  • Vitrakvi
  • Vitrakvi
  • Vitrakvi

Go Top